img

Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2024

Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
According to MRAResearch’s new survey, global Active Pharmaceutical Ingredients (API) CDMO market is projected to reach US$ 93530 million in 2033, increasing from US$ 53870 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Active Pharmaceutical Ingredients (API) CDMO market research.
The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Active Pharmaceutical Ingredients (API) CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Segment by Type
Macromolecular API
Small Molecule API

Segment by Application


Clinical
Commercial
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Active Pharmaceutical Ingredients (API) CDMO report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Macromolecular API
1.2.3 Small Molecule API
1.3 Market by Application
1.3.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Clinical
1.3.3 Commercial
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Perspective (2018-2033)
2.2 Active Pharmaceutical Ingredients (API) CDMO Growth Trends by Region
2.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Region (2018-2023)
2.2.3 Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Region (2024-2033)
2.3 Active Pharmaceutical Ingredients (API) CDMO Market Dynamics
2.3.1 Active Pharmaceutical Ingredients (API) CDMO Industry Trends
2.3.2 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
2.3.3 Active Pharmaceutical Ingredients (API) CDMO Market Challenges
2.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue
3.1.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue (2018-2023)
3.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Active Pharmaceutical Ingredients (API) CDMO Revenue
3.4 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio
3.4.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2022
3.5 Active Pharmaceutical Ingredients (API) CDMO Key Players Head office and Area Served
3.6 Key Players Active Pharmaceutical Ingredients (API) CDMO Product Solution and Service
3.7 Date of Enter into Active Pharmaceutical Ingredients (API) CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Type
4.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Type (2018-2023)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Type (2024-2033)
5 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Application
5.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Application (2018-2023)
5.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2033)
6.2 North America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
6.4 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2033)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
7.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2033)
8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2033)
9.2 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
9.4 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2033)
10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm
11.1.1 Recipharm Company Detail
11.1.2 Recipharm Business Overview
11.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Introduction
11.1.4 Recipharm Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.1.5 Recipharm Recent Development
11.2 Cambrex Corporation
11.2.1 Cambrex Corporation Company Detail
11.2.2 Cambrex Corporation Business Overview
11.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Introduction
11.2.4 Cambrex Corporation Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.2.5 Cambrex Corporation Recent Development
11.3 Patheon (Thermo Fisher Scientific)
11.3.1 Patheon (Thermo Fisher Scientific) Company Detail
11.3.2 Patheon (Thermo Fisher Scientific) Business Overview
11.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Introduction
11.3.4 Patheon (Thermo Fisher Scientific) Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.3.5 Patheon (Thermo Fisher Scientific) Recent Development
11.4 CordenPharma
11.4.1 CordenPharma Company Detail
11.4.2 CordenPharma Business Overview
11.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Introduction
11.4.4 CordenPharma Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.4.5 CordenPharma Recent Development
11.5 Lonza
11.5.1 Lonza Company Detail
11.5.2 Lonza Business Overview
11.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Introduction
11.5.4 Lonza Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.5.5 Lonza Recent Development
11.6 Siegfried
11.6.1 Siegfried Company Detail
11.6.2 Siegfried Business Overview
11.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Introduction
11.6.4 Siegfried Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.6.5 Siegfried Recent Development
11.7 Catalent
11.7.1 Catalent Company Detail
11.7.2 Catalent Business Overview
11.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Introduction
11.7.4 Catalent Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.7.5 Catalent Recent Development
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Detail
11.8.2 Boehringer Ingelheim Business Overview
11.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Introduction
11.8.4 Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.8.5 Boehringer Ingelheim Recent Development
11.9 Piramal Group
11.9.1 Piramal Group Company Detail
11.9.2 Piramal Group Business Overview
11.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.9.4 Piramal Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.9.5 Piramal Group Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Detail
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Introduction
11.10.4 AbbVie Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.10.5 AbbVie Recent Development
11.11 SGS Quay Pharmaceuticals
11.11.1 SGS Quay Pharmaceuticals Company Detail
11.11.2 SGS Quay Pharmaceuticals Business Overview
11.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Introduction
11.11.4 SGS Quay Pharmaceuticals Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.11.5 SGS Quay Pharmaceuticals Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Detail
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.12.4 Aenova Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.12.5 Aenova Group Recent Development
11.13 Curia
11.13.1 Curia Company Detail
11.13.2 Curia Business Overview
11.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Introduction
11.13.4 Curia Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.13.5 Curia Recent Development
11.14 Sterling Pharma Solutions
11.14.1 Sterling Pharma Solutions Company Detail
11.14.2 Sterling Pharma Solutions Business Overview
11.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Introduction
11.14.4 Sterling Pharma Solutions Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.14.5 Sterling Pharma Solutions Recent Development
11.15 Eurofins CDMO
11.15.1 Eurofins CDMO Company Detail
11.15.2 Eurofins CDMO Business Overview
11.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Introduction
11.15.4 Eurofins CDMO Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.15.5 Eurofins CDMO Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Macromolecular API
Table 3. Key Players of Small Molecule API
Table 4. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Region (2018-2023)
Table 8. Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Region (2024-2033)
Table 10. Active Pharmaceutical Ingredients (API) CDMO Market Trends
Table 11. Active Pharmaceutical Ingredients (API) CDMO Market Drivers
Table 12. Active Pharmaceutical Ingredients (API) CDMO Market Challenges
Table 13. Active Pharmaceutical Ingredients (API) CDMO Market Restraints
Table 14. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Players (2018-2023)
Table 16. Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2022)
Table 17. Ranking of Global Top Active Pharmaceutical Ingredients (API) CDMO Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Active Pharmaceutical Ingredients (API) CDMO Product Solution and Service
Table 21. Date of Enter into Active Pharmaceutical Ingredients (API) CDMO Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Type (2018-2023)
Table 25. Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Type (2024-2033)
Table 27. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Application (2018-2023)
Table 29. Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Application (2024-2033)
Table 31. North America Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 46. Recipharm Company Detail
Table 47. Recipharm Business Overview
Table 48. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product
Table 49. Recipharm Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 50. Recipharm Recent Development
Table 51. Cambrex Corporation Company Detail
Table 52. Cambrex Corporation Business Overview
Table 53. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product
Table 54. Cambrex Corporation Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 55. Cambrex Corporation Recent Development
Table 56. Patheon (Thermo Fisher Scientific) Company Detail
Table 57. Patheon (Thermo Fisher Scientific) Business Overview
Table 58. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product
Table 59. Patheon (Thermo Fisher Scientific) Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 60. Patheon (Thermo Fisher Scientific) Recent Development
Table 61. CordenPharma Company Detail
Table 62. CordenPharma Business Overview
Table 63. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product
Table 64. CordenPharma Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 65. CordenPharma Recent Development
Table 66. Lonza Company Detail
Table 67. Lonza Business Overview
Table 68. Lonza Active Pharmaceutical Ingredients (API) CDMO Product
Table 69. Lonza Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 70. Lonza Recent Development
Table 71. Siegfried Company Detail
Table 72. Siegfried Business Overview
Table 73. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product
Table 74. Siegfried Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 75. Siegfried Recent Development
Table 76. Catalent Company Detail
Table 77. Catalent Business Overview
Table 78. Catalent Active Pharmaceutical Ingredients (API) CDMO Product
Table 79. Catalent Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 80. Catalent Recent Development
Table 81. Boehringer Ingelheim Company Detail
Table 82. Boehringer Ingelheim Business Overview
Table 83. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product
Table 84. Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 85. Boehringer Ingelheim Recent Development
Table 86. Piramal Group Company Detail
Table 87. Piramal Group Business Overview
Table 88. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product
Table 89. Piramal Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 90. Piramal Group Recent Development
Table 91. AbbVie Company Detail
Table 92. AbbVie Business Overview
Table 93. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product
Table 94. AbbVie Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 95. AbbVie Recent Development
Table 96. SGS Quay Pharmaceuticals Company Detail
Table 97. SGS Quay Pharmaceuticals Business Overview
Table 98. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product
Table 99. SGS Quay Pharmaceuticals Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 100. SGS Quay Pharmaceuticals Recent Development
Table 101. Aenova Group Company Detail
Table 102. Aenova Group Business Overview
Table 103. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product
Table 104. Aenova Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 105. Aenova Group Recent Development
Table 106. Curia Company Detail
Table 107. Curia Business Overview
Table 108. Curia Active Pharmaceutical Ingredients (API) CDMO Product
Table 109. Curia Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 110. Curia Recent Development
Table 111. Sterling Pharma Solutions Company Detail
Table 112. Sterling Pharma Solutions Business Overview
Table 113. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product
Table 114. Sterling Pharma Solutions Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 115. Sterling Pharma Solutions Recent Development
Table 116. Eurofins CDMO Company Detail
Table 117. Eurofins CDMO Business Overview
Table 118. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product
Table 119. Eurofins CDMO Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023) & (US$ Million)
Table 120. Eurofins CDMO Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Type: 2022 VS 2033
Figure 3. Macromolecular API Features
Figure 4. Small Molecule API Features
Figure 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Application: 2022 VS 2033
Figure 7. Clinical Case Studies
Figure 8. Commercial Case Studies
Figure 9. Others Case Studies
Figure 10. Active Pharmaceutical Ingredients (API) CDMO Report Years Considered
Figure 11. Global Active Pharmaceutical Ingredients (API) CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Active Pharmaceutical Ingredients (API) CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Region: 2022 VS 2033
Figure 14. Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Players in 2022
Figure 15. Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2022
Figure 17. North America Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2018-2033)
Figure 19. United States Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2018-2033)
Figure 23. Germany Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Share by Region (2018-2033)
Figure 31. China Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2018-2033)
Figure 39. Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Share by Country (2018-2033)
Figure 43. Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Recipharm Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 46. Cambrex Corporation Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 47. Patheon (Thermo Fisher Scientific) Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 48. CordenPharma Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 49. Lonza Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 50. Siegfried Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 51. Catalent Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 52. Boehringer Ingelheim Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 53. Piramal Group Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 54. AbbVie Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 55. SGS Quay Pharmaceuticals Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 56. Aenova Group Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 57. Curia Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 58. Sterling Pharma Solutions Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 59. Eurofins CDMO Revenue Growth Rate in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed